Myriad Genetics's Total Assets for the quarter that ended in Dec. 2023 was $1,146.5 Mil.
During the past 12 months, Myriad Genetics's average Total Assets Growth Rate was -7.20% per year.
During the past 3 years, the average Total Assets Growth Rate was -5.40% per year.
During the past 5 years, the average Total Assets Growth Rate was -2.70% per year.
During the past 10 years, the average Total Assets Growth Rate was 8.60% per year.
During the past 13 years, Myriad Genetics's highest 3-Year average Total Assets Growth Rate was 62.00%. The lowest was -24.60%. And the median was 17.60%.
The historical data trend for Myriad Genetics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Myriad Genetics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (NAS:MYGN) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Myriad Genetics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Myriad Genetics Total Assets Related Terms
Thank you for viewing the detailed overview of Myriad Genetics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Myriad Genetics (Myriad Genetics) Business Description
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYGN has been successfully added to your 